A major deal in the pharma space, Teva says it will buy Allergan's generics business in a deal worth a little over 40 billion dollars. CNBC's Meg Tirrell reports the details.» Read More
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
"As a group, biotech is the place to be this year," said," Les Funtleyder, Poliwogg fund manager, discussing where to find attractive health care opportunities in 2013.
The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.
CNBC's Seema Mody reports the pharmaceutical and biotech sectors rally as the JPMorgan conference kicks off its second day.
Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.
The U.S. has given national security clearance to the purchase of an American DNA sequencing company by a Chinese firm, The New York Times reports.
Anti-virus software pioneer John McAfee is now firing back, reports CNBC's Robert Frank.
DuPont reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday, and announced plans to cut 1,500 jobs.
Pharmaceuticals continue to be an attractive sector for earnings and dividend growth, and CNBC's Seema Mody reports on how companies like Pfizer are faring.
If you're looking for beta, biotech might be your answer, reports CNBC's Seema Mody.
Thanks to several rounds of cost cutting and new product launches, cash balances across the pharma sector are increasing — because one analyst said we should see more cash being returned to shareholders via dividend.
Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.
The NYSE Arca Biotech index spacer hit an all-time high Monday, as investors continue to seek out the group for its above average growth prospects.
AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.
Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.
Investors need to see this as a speculative stock and take some profits as they come in, he said.
In the wake of Friday’s disappointing jobs report, “Mad Money” host Jim Cramer thinks investors need to prepare for the possibility of a recession.
With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.
“Mad Money” host Jim Cramer has the answer.
Last week, Celgene announced it was pulling its Revlimid application in Europe, and Mad Money host Jim Cramer explains why he thinks investors should buy into the stock now.